HYPERTENSION: Comparison of New Guidelines
|
|
- Benedict Cobb
- 8 years ago
- Views:
Transcription
1 HYPERTENSION: Comparison of New Guidelines L. Brian Cross, PharmD, BCACP, CDE Vice-Chair & Associate Professor Bill Gatton College of Pharmacy Department of Pharmacy Practice Associate Professor James H. Quillen College of Medicine Department of Family Medicine Objectives At the conclusion of the session, participants should be able to: Compare and contrast the 2013 ESH/ESC Hypertension Guidelines and the 2014 JNC8 Hypertension guidelines Understand the background data and development of the ESH/ESC and JNC8 guidelines Apply the recommendations to patient cases Impact of Hypertension 74.9% are treated 81.5% of patients aware of diagnosis 52.5% are controlled National Health and Nutrition Evaluation Survey
2 Evidence Timeline PEACE ACTION CAMELOT EUROPA REIN-2 JNC 7 ACCOMPLISH ONTARGET ACCORD-BP ESH/ESC HYVET AHA DREAM NICE ASTRONAUT ESH/ESC ACCF/AHA ALTITUDE NAVIGATOR JNC 8 FEVER JNC7 vs JNC8 JNC 8 Report. JAMA
3 Background/Development JNC8 Published 12/18/2013 in JAMA Evidence limited to RCTs only 3 Clinical Questions: 1 Does initiating antihypertensive therapy at a specific BP threshold improve outcomes? 2 Does treatment with antihypertensive therapy to a specific BP goal lead to improved outcomes? 3 Do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific outcomes? JNC 8 Report. JAMA 2013 Overview of JNC8 Recommendations Overview of JNC8 Recommendation Clinical Question Grade Key Trials 1 For pts >60 yo: Start tx at >150/90 with a goal of <150/90 2 For pts <60yo: start tx at >90 DBP and treat to goal of <90 DBP 3 For pts <60 yo: start tx at >140 SBP and treat to goal of <140 SBP 4 In pts >18yo with CKD, start tx at >140/90 and treat to goal of <140/90 5 For pts >18 yo with diabetes, start tx at >140/90 and treat to goal of <140/90 6 In nonblack (including diabetic) pts, initial tx should be a thiazide type diuretic, CCB, ACEI or ARB 7 In black pts (including those with diabetes), initial therapy should include a thiazide or CCB 8 For pts >18yo with CKD and hypertension, initial (or add on) tx should include an ACEI or ARB (regardless or race of DM status) 1,2 A HYVET, Syst-Eur, SHEP, JATOS, VALISH, CARDIO- SIS 1,2 A (30-59y0) E (18-29y0) HDFP, HTN-Stroke Cooperative, MRC, ANBP, VA Cooperative 1,2 E Expert Opinion 2 E Expert Opinion, AASK, MDRD, REIN-2 2 E SHEP, Syst-Eur, UKPDS, ACCORD-BP, Expert Opinion 3 B VA Cooperative, HDFP, SHEP 3 B (non-dm) C (DM pts) ALLHAT 3 B AASK 9 If goal not reached in 1 month, increase dose None E Expert Opinion or add 2 nd drug (CCB, thiazide, ACE or ARB) ACCORD-BP Intensive (SBP <120) vs. Standard (SBP <140) Randomized, open-label, multi-center trial 4,733 patients with hypertension, stable T2DM and high CV risk If established clinical CVD, years of age If 2 CV risks or subclinical CVD, years of age Achieved BP ~ 119/67 vs. 134/73 N Engl J Med 2010; 362:
4 ACCORD-BP: Efficacy N Engl J Med 2010; 362: ACCORD-BP: Safety N Engl J Med 2010; 362: HOT Trial Major Cardiovascular Events After 4 Years Hansson L, et al. Lancet 1998;351:
5 Elderly 2009 Critical analysis of designed trials Baselines mostly >160, treatment rarely attaining <140 ESH/ESC Guidelines for arterial hypertension. Eur Heart J Zanchetti A, et al. J Hypertens 2009; 27: Overview of JNC8 Recommendations Overview of JNC8 Recommendation Clinical Question Grade Key Trials 1 For pts >60 yo: Start tx at >150/90 with a goal of <150/90 2 For pts <60yo: start tx at >90 DBP and treat to goal of <90 DBP 3 For pts <60 yo: start tx at >140 SBP and treat to goal of <140 SBP 4 In pts >18yo with CKD, start tx at >140/90 and treat to goal of <140/90 5 For pts >18 yo with diabetes, start tx at >140/90 and treat to goal of <140/90 6 In nonblack (including diabetic) pts, initial tx should be a thiazide type diuretic, CCB, ACEI or ARB 7 In black pts (including those with diabetes), initial therapy should include a thiazide or CCB 8 For pts >18yo with CKD and hypertension, initial (or add on) tx should include an ACEI or ARB (regardless or race of DM status) 1,2 A HYVET, Syst-Eur, SHEP, JATOS, VALISH, CARDIO- SIS 1,2 A (30-59y0) E (18-29y0) HDFP, HTN-Stroke Cooperative, MRC, ANBP, VA Cooperative 1,2 E Expert Opinion 2 E Expert Opinion, AASK, MDRD, REIN-2 2 E SHEP, Syst-Eur, UKPDS, ACCORD-BP, Expert Opinion 3 B VA Cooperative, HDFP, SHEP 3 B (non-dm) C (DM pts) ALLHAT 3 B AASK 9 If goal not reached in 1 month, increase dose None E Expert Opinion or add 2 nd drug (CCB, thiazide, ACE or ARB) Lots of Options for First Line Therapy 2008 ACCOMPLISH CV event reduction ACEi+CCB > ACEi+Thiazide with similar BP lowering More later 2011 NICE Guidelines Limited evidence for conferred benefit of initial therapy with low dose thiazide [comparatively] 2013 ESH/ESC Guidelines Older guidance (thiazides preferred/only 1 st line) NOT supported by a more extensive review of evidence Dorsch M, et al. Hypertension 2011; 57: ESH/ESC Guidelines for arterial hypertension. Eur Heart J National Institute for Health and Clinical Excellence. Hypertension (CG127). N Engl J Med 2008; 359:
6 except Beta-blockers 2007 Cochrane Collaboration 13 RCTs (91,561 patients) Relative Risk (95% CI) Comparator CV Disease Stroke Death Placebo 0.88 ( ) 0.80 ( ) 0.99 ( ) Thiazide 1.13 ( ) 1.17 ( ) 1.04 ( ) ACEi/ARB 1.0 ( ) 1.3 ( ) 1.1 ( ) CCB 1.18 ( ) 1.24 ( ) 1.07 ( ) Cochrane Database of Systematic Reviews. 2007, Issue 1. Art No.: CD002003: ESH/ESC Guidelines for arterial hypertension. Eur Heart J Saseen J. Good Things Come to Those Who Wait? ASHP 2012 Presentation. and in African Americans JNC 8 specific considerations ALLHAT subgroup analyses Cerebrovascular, HF, and CV outcomes Thiazide diuretic > ACEi Stroke ACEi 51% higher rate than CCB All outcomes except HF prevention Thiazide diuretic = CCB However, must consider CKD Arch Intern Med 2008; 168(2): JNC 8 Report. JAMA For Diabetes 2008 DREAM & 2010 NAVIGATOR No significant improvement Diabetes Care 2008; 31: N Engl J Med 2010; 362: JNC 7 Report. JAMA
7 Thiazide means HCTZ, right? HCTZ effect on Morbidity/Mortality VA Cooperative: HCTZ 100mg + reserpine MRC: HCTZ 25-50mg + amiloride EWPHE: HCTZ + triamterene ANBP2: HCTZ dose not specified Chlorthalidone SHEP, ALLHAT Indapamide HYVET MRFIT ACCOMPLISH Messerli et al. Am J Med. 2011;124: JNC8 Algorithm- Initial Therapy JNC 8 Report. JAMA 2013 JNC8 Algorithm- Add On Therapy JNC 8 Report. JAMA
8 ESH/ESC Guidelines: Risk Assessment ESH/ESC Guidelines ESH/ESC Guidelines for arterial hypertension. Eur Heart J
9 ESH/ESC Guidelines ESH/ESC Guidelines for arterial hypertension. Eur Heart J 2013 Treatment With Compelling Indications JNC 7 ESH/ESC ESH/ESC Guidelines for arterial hypertension. Eur Heart J JNC 7 Report. JAMA Beta Blockers as First Line Therapy? Cochrane meta analysis: Beta-blockers may be inferior to some, but not all, other drug classes for some outcomes Total mortality and CV events: BB < CCB Stroke: BB < CCB and RAS blockers CHD: BB = CCB, RAS blockers and diuretics Law et al. Effective in post MI and CHF Equal to other classes in preventing coronary outcomes ESH/ESC Guidelines for arterial hypertension. Eur Heart J
10 ESH/ESC Guidelines ESH/ESC Guidelines for arterial hypertension. Eur Heart J 2013 ESH/ESC Guidelines ESH/ESC Guidelines for arterial hypertension. Eur Heart J 2013 ESH/ESC Guidelines for arterial hypertension. Eur Heart J
11 Highlighted Treatment Goal Updates Parameter JNC 7 ESH/ESC JNC 8 CKD <130/80 <140/90 <140/90 Diabetes <130/80 <140/80-85 <140/90 Elderly <140/90 fit <140/90, nonfit <150/90 <150/90 * *Achieving <140/90 is acceptable barring tolerability ESH/ESC Guidelines for arterial hypertension. Eur Heart J JNC 7 Report. JAMA JNC 8 Report. JAMA Treatment Without Compelling Indications Drug Class ESH/ESC JNC 8 ACE inhibitor non-blacks blacks ARB non-blacks blacks BB? CCB Thiazide diuretic ESH/ESC Guidelines for arterial hypertension. Eur Heart J JNC 8 Report. JAMA JNC8 vs ESH/ESC JNC 8 Report. JAMA
12 Controversy and Discord 29% of JNC-8 writers dissented Did they get the thresholds right? Performance Measures Patient Education Cases SP is a 54 yo WM who presents to your clinic for a primary care appointment. His BP today is 164/90, taken appropriately. At his last visit 3 months ago, his BP was 156/88, also taken appropriately. SP does not monitor his BP at home. Upon questioning, you find that he does not smoke, has not had any caffeine today, and took all of his morning medications. He has no complaints and is feeling well today. He has a history of T2DM, Dyslipidemia, COPD, allergic rhinitis, esophageal reflux, and osteoarthritis. What is SP s blood pressure goal? A. <130/80 B. <140/80 C. <140/90 D. <140/85 12
13 What medication, if any, would you initiate for SP s blood pressure? A. Therapeutic lifestyle changes and lisinopril 10mg daily B. Therapeutic lifestyle changes and HCTZ 25mg daily C. Therapeutic lifestyle changes and re-evaluate in 4 weeks for the need to add medication D. Therapeutic lifestyle changes and metoprolol tartrate 25mg BID How might your management change if SP were a 54yo AAM? A. Initiate therapy with lisinopril/hctz rather than lisinopril alone B. Initiate therapy with HCTZ alone C. Initiate therapy with amlodipine alone D. Initiate therapy with HCTZ and amlodipine How would your management change if SP s Scr were 2.9 (est Crcl = 28 ml/min)? A. BP goal would change to <130/80 B. Change HCTZ to furosemide C. Discontinue lisinopril D. Continue current management as all doses are appropriate for current renal function 13
14 References Mancia G, Fagard R, Narkiewicz K, et al ESH/ESC guideline for the management of arterial hypertension. J Hypertens. 2013; 31: James PA, Oparil S, Carter BL, et al Evidence-based guidlelines for the management of high blood pressure in adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013;. doi: /jama Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug classon progression of hypertensive kidney disease: results from the AASK trial.; African American Study of Kidney Disease and Hypertension Study Group. JAMA 2002 Nov 20;288(19): Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000 Apr 19;283(15): Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-ii receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987 Jun 4;316(23): Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure.atlas Study Group. Circulation 1999 Dec 7;100(23): Yusuf S, Sleight P, Pogue J, et al. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med : Effects of ramipril on cardiovascular & microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 Jan 22;355(9200): Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT)randomised trial. HOT Study Group. Lancet 1998 Jun 13;351(9118):1755. References Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 Sep 26;102(13): Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Lancet 2002 Sep 7;360(9335): Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy; RENAAL Study Investigators. N Engl J Med 2001 Sep 20;345(12): Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991 Jun 26;265(24): Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997 Sep 13;350(9080): Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators (Syst-Eur). N Engl J Med 1999 Mar 4;340(9): Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 Sep 12;317(7160): Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure (Val-HeFT); Valsartan Heart Failure Trial Investigators. N Engl J Med 2001 Dec 6;345(23): Questions? crossl@etsu.edu 14
Treatment of Hypertension: JNC 8 and More
PL Detail-Document #300201 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Treatment of
More informationSpecial Communication
Clinical Review & Education Special Communication 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National
More informationHypertension and Diabetes
Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas
More informationSupplementary Online Content
Supplementary Online Content James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed to the Eighth Joint National
More informationDrug Treatment in Type 2 Diabetes with Hypertension
Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk
More informationManagement of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) Adapted by Capital Health Plan Approved by Quality Improvement
More informationAggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
More informationUse of antihypertensive medications in patients with diabetes in Ajman, UAE
Use of antihypertensive medications in patients with diabetes in Ajman, UAE Mohammed Arifulla 1*, Lisha J John 1, Jayadevan Sreedharan 2, Jayakumary Muttappallymyalil 2, Jenny Cheriathu 3, Sheikh Altaf
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationAntihypertensive Drug Management to Achieve Systolic Blood Pressure <120 mmhg in SPRINT
Antihypertensive Drug Management to Achieve Systolic Blood Pressure
More informationCombination Antihypertensive Therapy: When to use it Diabetes
Combination Antihypertensive Therapy: When to use it Diabetes George L. Bakris, MD, F.A.S.N., F.A.S.H. Professor of Medicine Director, ASH Comprehensive Hypertension Center The University of Chicago Medicine
More informationDRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More informationPharmacologic Management of Hypertension in Patients with Diabetes
Pharmacologic Management of Hypertension in Patients with Diabetes KAREN L. WHALEN, PharmD, University of Florida College of Pharmacy St. Petersburg Campus, Seminole, Florida ROBERT D. STEWART, PharmD,
More informationTreatment Issues of Diabetes, Hypertension, and Lipids in the Elderly Patient
Treatment Issues of Diabetes, Hypertension, and Lipids in the Elderly Patient 17 th Primary Care Conference March 26, 2013 L. Brian Cross, PharmD, BCACP, CDE Chad K. Gentry, PharmD, BCACP, CDE Objectives
More informationCarefully review the risks and potential, but unproven, benefits of treatment.
Hypertension This is a consensus guideline for the pharmacological management of hypertension with frailty. This information was developed by the Dalhousie University Academic Detailing Service and the
More informationADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines for the monitoring of antihypertensive therapy in adult patients and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident.
More informationBlood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis
Research Original Investigation A Systematic Review and Meta-analysis Connor A. Emdin, HBSc; Kazem Rahimi, DM, MSc; Bruce Neal, PhD; Thomas Callender, MBChB; Vlado Perkovic, PhD; Anushka Patel, PhD IMPORTANCE
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationHypertension and Heart Failure Medications. Dr William Dooley
Hypertension and Heart Failure Medications Dr William Dooley Plan Heart Failure Acute vs. chronic Mx Hypertension Common drugs used Method of action Choice of medications Heart Failure Aims; Short term:
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
More informationDrug Treatment for People with Hypertension
Treatment algorithm Drug treatment for essential HT Compelling indication / contraindication over choice of drug No Yes Go to Appendix 1 Start with either ACEI (or ARB if ACEI intolerant), calcium channel
More informationCorrespondence to: Rima B Shah (rima_1223@yahoo.co.in) DOI: 10.5455/ijmsph.2013.2.167-172 Received Date: 29.11.2012 Accepted Date: 03.12.
RESEARCH ARTICLE STUDY OF UTILIZATION PATTERN OF ANTI-HYPERTENSIVE DRUGS IN HYPERTENSIVE DIABETIC PATIENTS WITH OR WITHOUT REDUCED RENAL FUNCTION AT TERTIARY CARE TEACHING HOSPITAL Jay Shah 1, Tejas Khakhkhar
More informationBlood Pressure Goals for Diabetic Patients Over 60 Years of Age: Is It Time They Earned Some Slack?
Blood Pressure Goals for Diabetic Patients Over 60 Years of Age: Is It Time They Earned Some Slack? Objectives: Ashley Marshall, PharmD PGY-1 Pharmacy Resident South Texas Veterans Health Care System,
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationVilken evidens finns för att blodtrycksmålet 130/80 mmhg leder till färre komplikationer än systoliskt blodtryck under 140 mmhg vid DM2?
Kardiovaskulära Vårmötet Örebro 2011 Vilken evidens finns för att blodtrycksmålet 130/80 mmhg leder till färre komplikationer än systoliskt blodtryck under 140 mmhg vid DM2? Peter M Nilsson Institutionen
More informationDiabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
More informationHypertension Management Action Guide for Health Care Providers
1 Hypertension Management Action Guide for Health Care Providers 2 For more information, please contact: Gayathri Suresh Kumar, MD Medical Officer Chronic Disease, Healthy Behaviors, and Injury Epidemiology
More informationGuidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims
Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationNearly one in four adults
COVER ARTICLE Controlling Hypertension in Patients with Diabetes SHERRI L. KONZEM, PHARM.D., B.C.P.S. Memorial Family Practice Residency and University of Houston College of Pharmacy, Houston, Texas VICTORIA
More informationDiabetes Care 23:888 892, 2000
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Therapeutic Benefits of ACE Inhibitors and Other Antihypertensive Drugs in Patients With Type 2 Diabetes MARCO PAHOR, MD BRUCE M. PSATY,
More informationType 2 diabetes mellitus is a common disease with substantial
Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Sandeep Vijan, MD, MS, and Rodney A. Hayward, MD Clinical Guidelines
More informationHypertension in Chronic Kidney Disease Vito M. Campese, MD
Hypertension in Chronic Kidney Disease Vito M. Campese, MD Professor of Medicine, Physiology and Biophysics Division of Nephrology and Hypertension Center Co-Director USC/UKRO Kidney Research Center Keck
More informationUsing multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration
Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration Hiddo Lambers Heerspink Department of Clinical Pharmacology University Medical
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationCase Study 6: Management of Hypertension
Case Study 6: Management of Hypertension 2000 Scenario Mr Ellis is a fit 61-year-old, semi-retired market gardener. He is a moderate (10/day) smoker with minimal alcohol intake and there are no other cardiovascular
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationCan Common Blood Pressure Medications Cause Diabetes?
Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately
More informationAppropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial
Appropriate in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Robert W Schrier*, Raymond O Estacio, Philip S Mehler and William R Hiatt SUMMARY The hypertensive and
More information22 Treatment of Hypertension
Chapter 22 / Elderly Hypertensive Diabetics 451 22 Treatment of Hypertension in the Elderly Patient With Diabetes James R. Sowers, MD, FACE, FACP, FAHA and L. Michael Prisant, MD, FACC, FACP CONTENTS OVERVIEW
More informationRenovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationIn many diabetes units, people with type
Renal Microalbuminuria: Screening and management in type 2 diabetes Julia Arundale Introduction In many diabetes units, patients with type 1 or type 2 diabetes are screened for proteinuria. Screening for
More informationThe incidence of cardiovascular disease (CVD)
Review Paper Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead Rigas Kalaitzidis, MD; George Bakris, MD The incidence of type 2 diabetes is increasing in the United
More informationEvaluation of anti-hypertensive drug utilisation and cost in Hospital Tengku Ampuan Afzan, Kuantan.
Evaluation of anti-hypertensive drug utilisation and cost in Hospital Tengku Ampuan Afzan, Kuantan. Azarisman SMS a,e, Aszrin A b, Sahimi M d, Ngow HA a,e, Marzuki AO a, Jamalludin AR c, Sapari S d and
More informationNew in Diabetes. Diabetes is becoming more common. By the. What s. Presented at McMaster University, Hamilton, Ontario, October 2001.
Focus on CME at McMaster University What s New in Diabetes By Sarah Capes, MD, FRCPC Presented at McMaster University, Hamilton, Ontario, October 2001. Diabetes is becoming more common. By the year 2025,
More informationPrevention and management of chronic kidney disease in type 2 diabetes
162..194 NEPHROLOGY 2010; 15, S162 S194 doi:10.1111/j.1440-1797.2010.01240.x Prevention and management of chronic kidney disease in type 2 diabetes Date written: April 2009nep_1240 Final submission: April
More informationT he treatment of hypertension in type
D I A B E T E S, O B E S I T Y & H Y P E R T E N S I O N O U T C O M E S T U D I E S Diabetes, Hypertension, and Outcome Studies: Overview 2010 PETER M. NILSSON, MD, PHD 1 JAN CEDERHOLM, MD, PHD 2 T he
More informationCase study 28: Managing hypertension in diabetes
Case study 28: Managing hypertension in diabetes October 2003 An Independent, Australian organisation for Quality Use of Medicines National Prescribing Service Limited ACN 082 034 393 Level 7/418A Elizabeth
More informationHypertension Guideline V4
Hypertension Guideline V4 Approved 24/06/2008 Version VERSION 4 FINAL Date of First Issue 26/02/08 Review Date 01/03/2010 Date of Issue 24/06/2008 EQIA Yes / No 24/06/2008 Author / Contact Dr Leslie Cruickshank
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationHypertension Guidelines
Overview Hypertension Guidelines Aim to reduce Blood Pressure to 140/90 or less (140/80 for diabetics), adding drugs as needed until further treatment is inappropriate or declined. N.B. patients do not
More informationApproaches to the Management of Difficult-to-Control Hypertension
Approaches to the Management of Difficult-to-Control Theodore D Fraker, Jr, MD Professor of Medicine The Ohio State University Medical Center Orlando, Florida October 7-9, 2011 Case Study: DM 64 year old
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Protocol Version 4.0. November 1, 2012
Systolic Blood Pressure Intervention Trial (SPRINT) Protocol Version 4.0 November 1, 2012 Table of Contents Executive Summary... 1 Chapter 1 Introduction and Background... 3 Chapter 2 Overview of Trial
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationInitial Treatment of Hypertension
The new england journal of medicine clinical practice Initial Treatment of Hypertension Phyllis August, M.D., M.P.H. This Journal feature begins with a case vignette highlighting a common clinical problem.
More informationElevated Blood Pressure Among U.S. Adults with Diabetes, 1988 1994
Elevated Blood Pressure Among U.S. Adults with Diabetes, 1988 1994 Linda S. Geiss, MA, Deborah B. Rolka, MS, Michael M. Engelgau, MD, MS Background: Methods: Results: Conclusions: Recent guidelines and
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationPROCEEDINGS DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT
DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT Diabetic nephropathy affects people with either type 1 or type 2 diabetes mellitus.
More informationC h a p t e r 4 4 Diabetes and Hypertension
C h a p t e r 4 4 Diabetes and Hypertension Harbir Kaur Rao 1, RS Gupta 1, AR Singh 1 Professor of Medicine, Government Medical College, Patiala, Punjab The person with diabetes who knows the most lives
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationAssess adherence with medication and lifestyle changes at every opportunity and intervene if necessary
PPR thirty eight Prescribing Practice Review For Primary Care July 2007 Managing hypertension as a cardiovascular risk factor Key Messages Assess absolute cardiovascular risk and manage hypertension along
More informationTips and tricks in hypertension
Tips and tricks in hypertension Domenic Sica, M.D. Professor of Medicine and Pharmacology Chairman, Section of Clinical Pharmacology and Hypertension Division of Nephrology Virginia Commonwealth University
More informationHypertension Diagnosis and Treatment Guideline
Hypertension Diagnosis and Treatment Guideline Major Changes as of August 2014... 2 Preface... 3 Exclusions... 3 Prevention... 3 Screening... 3 Diagnosis... 4 Treatment Goals... 5 Initiating Treatment...
More informationTreating Hypertension in the Patient With Overt Diabetic Nephropathy. Edmund J. Lewis, MD
Treating Hypertension in the Patient With Overt Diabetic Nephropathy Edmund J. Lewis, MD Summary: Arterial blood pressure is a major determinant of renal and cardiovascular outcomes in diabetic nephropathy.
More informationWomen and CVD: Overview
Percent HYPERTENSION In Women Ravi Thadhani MD, MPH Professor of Medicine Harvard Medical School Chief, Division of Nephrology Massachusetts General Hospital Women and CVD: Overview *Disclosures: Consultant
More information( Diabetic nephropathy) ( Microalbuminuria ) ( Macroalbuminuria )
2006 17 99-105 2006 20-40% ( ESRD ) 30 299 mg ( ) ( 300 mgday ) DCCBs ) dihydropyridine calcium channel blockers ( non- DCCBs ( -blockers ( diuretics ) 10%) 0.8 ( 60 mlmin per 1.73 m 2 30 mlmin per 1.73
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationHYPERCHOLESTEROLAEMIA STATIN AND BEYOND
HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause
More informationDrug treatment of elevated blood pressure
Drug treatment of elevated blood pressure Mark Nelson, Professor and Chair, Discipline of General Practice Professorial Research Fellow, and Senior Member, Menzies Research Institute, University of Tasmania,
More informationQuiz 5 Heart Failure scores (n=163)
Quiz 5 Heart Failure summary statistics The correct answers to questions are indicated by *. Students were awarded 2 points for question #3 for either selecting spironolactone or eplerenone. However, the
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES:
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationHypertension is an extremely common
Reviews/Commentaries/Position T E C H N I C A L R E V I E W Statements The Treatment of Hypertension in Adult Patients With Diabetes CARLOS ARAUZ-PACHECO, MD 1 MARIAN A. PARROTT, MD, MPH 2 PHILIP RASKIN,
More informationUsing an EMR to Improve Quality of Care in a National Network
Using an EMR to Improve Quality of Care in a National Network James M. Gill, MD, MPH Associate Professor of Family Medicine Senior Scientist in Health Policy Jefferson Medical College, Philadelphia, PA
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationMicroalbuminuria: We are in the midst of an epidemic: the epidemic. So What s a Little Protein? Malcolm s diabetes. How much is too much?
Focus on CME at the University of Saskatchewan Microalbuminuria: So What s a Little Protein? By Judith T. Klassen, BSc, MD, FRCPC University of Saskatchewan Practical Management of Common Medical Problems
More informationReport of the Expert Committee for the Selection and Inclusion of Medicines in the Pan American Health Organization Strategic Fund July 2013
Report of the Expert Committee for the Selection and Inclusion of Medicines in the Pan American Health Organization Strategic Fund July 2013 Report of the Expert Committee / A Report of the Expert Committee
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationResearch Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources
Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources James Floyd, MD, MS Sep 17, 2015 UW Hospital Medicine Faculty Development Program Objectives Become more
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Diuretic-Based Treatment and Cardiovascular Events in Patients With Mild Renal Dysfunction Enrolled in the Systolic Hypertension in the Elderly Program Marco Pahor, MD; Ronald I.
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease
Editorial review Keywords: diabetic nephropathy, microalbuminuria, ACE inhibition, AT-receptor blockade, glomerulopathy, hypertension, blood pressure, macrovascular disease, diabetes mellitus Aarhus University
More informationTreating Microalbuminuria
Background Diabetic nephropathy is the most common cause of end stage renal disease (ESRD). In diabetes, high blood glucose causes glomerular hyperfiltration and triggers inflammation, oxidative damage,
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationObserved Benefits of Antihypertensive Drug Treatment Results of the Trials of Traditional Therapy
1-36 Observed Benefits of Antihypertensive Drug Treatment Results of the Trials of Traditional Therapy Controlled Clinical Trials of Drug Treatment for Hypertension A Review Jeffrey A. Cutler, Stephen
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationHow High Should an ACE Inhibitor or Angiotensin Receptor Blocker Be Dosed in Patients with Diabetic Nephropathy?
How High Should an ACE Inhibitor or Angiotensin Receptor Blocker Be Dosed in Patients with Diabetic Nephropathy? Marc S. Weinberg, MD, Nicholas Kaperonis, MD, and George L. Bakris, MD* Address *Hypertension
More informationMar. 31, 2011 (202) 690-6145. Improving Quality of Care for Medicare Patients: Accountable Care Organizations
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More information